Pfizer EVP granted 82,284 stock appreciation rights

Pfizer Inc. Executive Vice President Lidia Fonseca reported receiving a grant of 82,284 stock appreciation rights on Pfizer common stock.

Accepted by SEC EDGAR 03/05/2026 - 05:25 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Pfizer Inc. Executive Vice President Lidia Fonseca reported receiving a grant of 82,284 stock appreciation rights on Pfizer common stock. These rights were acquired as a compensation award at a price of $0.0000 per right and are held as direct ownership.

According to the disclosure, the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this grant, Fonseca held a total of 82,284 stock appreciation rights.

Insider Trade Summary

Grant/Award: 82,284 shares

Grant/Award 1 txn

Insider Fonseca Lidia

Role Executive Vice President

Type	Security	Shares	Price	Value
Grant/Award	Stock Appreciation Rights	82,284	$0.00	$0.00

Holdings After Transaction: Stock Appreciation Rights — 82,284 contracts (Direct)

Holdings Before and After: Stock Appreciation Rights, 0 to 82,284 contracts (Direct)

Footnotes (1)

1. F1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pfizer (PFE) report for Lidia Fonseca?

Pfizer reported that Executive Vice President Lidia Fonseca received a grant of 82,284 stock appreciation rights. These derivative awards relate to Pfizer common stock and represent a form of equity-based compensation rather than an open-market stock purchase or sale.

How many stock appreciation rights did Lidia Fonseca receive at Pfizer (PFE)?

Lidia Fonseca received 82,284 stock appreciation rights tied to Pfizer common stock. This entire amount was acquired in a single compensation award, leaving her with 82,284 such rights directly owned immediately after the reported transaction.

At what price were the stock appreciation rights granted to Lidia Fonseca at Pfizer (PFE)?

The stock appreciation rights were granted to Lidia Fonseca at a stated price of $0.0000 per right. This indicates a compensatory grant rather than a purchase, meaning she did not pay cash consideration to acquire these derivative awards.

When will Lidia Fonseca’s Pfizer (PFE) stock appreciation rights be settled?

The stock appreciation rights granted to Lidia Fonseca will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. Settlement timing is therefore tied to a long-term vesting and holding period structure.

Are Lidia Fonseca’s Pfizer (PFE) stock appreciation rights subject to vesting conditions?

Yes. The filing states that Lidia Fonseca’s stock appreciation rights are subject to certain vesting requirements. These conditions must be satisfied before the rights are ultimately settled in shares of Pfizer common stock on the fifth anniversary of the grant date.

Does Lidia Fonseca hold her Pfizer (PFE) stock appreciation rights directly or indirectly?

The Form 4 shows that Lidia Fonseca holds the 82,284 stock appreciation rights as direct ownership. There is no indication that these awards are held through a separate trust, partnership, or other indirect ownership vehicle in this disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fonseca Lidia

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$26.58	03/03/2026		A		82,284		03/03/2031(1)	03/03/2031(1)	Common Stock	82,284	$0.0000	82,284	D

Explanation of Responses:

1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

	/s/ Shanice A. Reid, by power of atty, for Lidia Fonseca	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.